Firefly Neuroscience shares rise 40.18% in intraday after signing public-private partnership with US Department of War to deploy its AI-driven EEG/ERP platform for treating military PTSD and TBI.

Firefly Neuroscience surged 40.18% in intraday trading, driven by an announcement on March 26, 2026, of a public-private partnership with the U.S. Department of War to deploy its FDA-cleared, AI-driven EEG/ERP technology platform for assessing and treating PTSD and TBI in active duty and veteran military personnel, expanding the company's commercial footprint into the U.S. government and defense health sectors.